epoetin-alfa and Heart-Diseases

epoetin-alfa has been researched along with Heart-Diseases* in 5 studies

Reviews

2 review(s) available for epoetin-alfa and Heart-Diseases

ArticleYear
Blood conservation in a congenital cardiac surgery program.
    AORN journal, 2008, Volume: 87, Issue:6

    Bloodless surgery programs are being instituted because of increasing public concerns about blood transfusions and the need to accommodate some patients' religious beliefs. Patients' desires to forego transfusion must be identified during the preoperative screening process and subsequently reflected on the surgical consent. Patients are managed preoperatively with erythropoietin and dietary supplements. The surgical team employs a variety of intraoperative and postoperative blood conservation techniques to help avoid the need for transfusion. A retrospective review of congenital cardiac procedures in a blood conservation program confirmed that bloodless cardiac surgery is effective.

    Topics: Blood Loss, Surgical; Blood Transfusion; Child, Preschool; Christianity; Epoetin Alfa; Erythropoietin; Heart Diseases; Hematinics; Humans; Infant; Perioperative Nursing; Recombinant Proteins; Retrospective Studies

2008
Iron and anemia in human biology: a review of mechanisms.
    Heart failure reviews, 2008, Volume: 13, Issue:4

    The biology of iron in relation to anemia is best understood by a review of the iron cycle, since the majority of iron for erythropoiesis is provided by iron recovered from senescent erythrocytes. In iron-deficiency anemia, storage iron declines until iron delivery to the bone marrow is insufficient for erythropoiesis. This can be monitored with clinical indicators, beginning with low plasma ferritin, followed by decreased plasma iron and transferrin saturation, and culminating in red blood cells with low-Hb content. When adequate dietary iron is provided, these markers show return to normal, indicating a response to the dietary supplement. Anemia of inflammation (also known as anemia of chronic disease, or ACD) follows a different course, because in this form of anemia storage iron is often abundant but not available for erythropoiesis. The diagnosis of ACD is more difficult than the diagnosis of iron-deficiency anemia, and often the first identified symptom is the failure to show a response to a dietary iron supplement. Confirmation of ACD is best obtained from elevated markers of inflammation. The treatment of ACD, which typically employs erythropoietin (EPO) supplements and intravenous iron (i.v.-iron), is empirical and often falls shorts of therapeutic goals. Dialysis patients show a complex pattern of anemia, which results from inadequate EPO production by the kidney, inflammation, changes in nutrition, and blood losses during treatment. EPO and i.v.-iron are the mainstays of treatment. Patients with heart failure can be anemic, with incidence as high as 50%. The causes are multifactorial; inflammation now appears to be the primary cause of this form of anemia, with contributions from increased plasma volume, effects of drug therapy, and other complications of heart disease. Discerning the mechanisms of anemia for the heart failure patient may aid rational therapy in each case.

    Topics: Anemia; Anemia, Iron-Deficiency; Chronic Disease; Epoetin Alfa; Erythropoietin; Female; Heart Diseases; Hematinics; Humans; Inflammation; Iron; Kidney Diseases; Male; Recombinant Proteins

2008

Trials

1 trial(s) available for epoetin-alfa and Heart-Diseases

ArticleYear
Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:7

    It is unclear whether physiologic hemoglobin targets lead to cardiac benefit in incident hemodialysis patients without symptomatic heart disease and left ventricular dilation. In this randomized, double-blind study, lower (9.5 to 11.5 g/dl) and higher (13.5 to 14.5 g/dl) hemoglobin targets were generated with epoetin alpha over 24 wk and maintained for an additional 72 wk. Major eligibility criteria included recent hemodialysis initiation and absence of symptomatic cardiac disease and left ventricular dilation. The primary outcome measure was left ventricular volume index (LVVI). The study enrolled 596 patients. Mean age, duration of dialysis therapy, baseline predialysis hemoglobin, and LVVI were 50.8 yr, 0.8 yr, 11.0 g/dl, and 69 ml/m2, respectively; 18% had diabetic nephropathy. Mean hemoglobin levels in the higher and lower target groups were 13.3 and 10.9 g/dl, respectively, at 24 wk. Percentage changes in LVVI between baseline and last value were similar (7.6% in the higher and 8.3% in the lower target group) as were the changes in left ventricular mass index (16.8 versus 14.2%). For the secondary outcomes, the only between-group difference was an improved SF-36 Vitality score in the higher versus the lower target group (1.21 versus -2.31; P = 0.036). Overall adverse event rates were similar in both target groups; higher (P < 0.05) rates of skeletal pain, surgery, and dizziness were seen in the lower target group, and headache and cerebrovascular events were seen in the higher target group. Normalization of hemoglobin in incident hemodialysis patients does not have a beneficial effect on cardiac structure, compared with partial correction.

    Topics: Adult; Aged; Anemia; Double-Blind Method; Epoetin Alfa; Erythropoietin; Female; Heart Diseases; Hematinics; Humans; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis

2005

Other Studies

2 other study(ies) available for epoetin-alfa and Heart-Diseases

ArticleYear
Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Comorbidity; Drug Resistance; Epoetin Alfa; Erythropoietin; Heart Diseases; Hematocrit; Humans; Recombinant Proteins; Renal Dialysis; Risk Factors

1998
Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Epoetin Alfa; Erythropoietin; Extracellular Space; Heart Diseases; Hematocrit; Humans; Plasma Volume; Recombinant Proteins; Renal Dialysis

1998